"Roadmap to a cure" sounds like a great theme for a medical conference but clinicians involved with pulmonary hypertension (PH) may view the title with more than a little skepticism because we all know how much work lies ahead before a cure can truly be achieved. The roadmap is actually elusive and the path has many pitfalls. Nevertheless, if the organizers of this year's Seventh International Pulmonary Hypertension Conference and Scientific Sessions reached a bit too far with their title for what is actually not yet within our grasp, they also created Scientific Sessions filled with so much promise and hope that perhaps all attendees came away sensing that, indeed, we are not far from creating the roadmap to a cure. At least the sessions gave us another touchstone, a reference point and glimpse of signs guiding us in this direction.
The collaboration between the patient and caregiver community and the research community at the biennial PHA Conference has its roots in the first conference and the foresight demonstrated by Dr Elliott. From the start, he recognized the unique opportunity to perform clinical research as part of the mission of each of the conferences to contribute toward important advances in the understanding of PAH. At that first meeting, he collected information and DNA from 40 subjects. "In one weekend, I was able to collect what would have otherwise taken 5 years," says Dr Elliott. After meeting with patients and their families and recruiting these patients to help with his research program, Dr Elliott "felt that I had to give something back to the PH community, to continue to work together to solve the puzzle of PH." He continued to participate actively in PHA conferences, both as a teacher and researcher. He made the "research room" available to others. At this past year's conference, more than 150 persons participated in several research protocols designed to add insight into the pathogenesis and therapy of this illness.
Dr Elliott earned his MD from the University of Maryland. After residency at Maryland and a Fellowship in Pulmonary Diseases at the University of Utah, he has spent most of his career in Salt Lake City where he is Professor of Medicine at the University of Utah and Chief of the Pulmonary and Critical Care Medicine Division at the LDS Hospital. His interest in the pulmonary circulation began as a fellow at Utah where he studied vascular changes associated with acute respiratory distress syndrome by administering vasodilators to patients. "While the treatment did not help these patients, this study encouraged my interest in the pulmonary circulation." After a brief return to his home state of Maryland, Dr Elliott returned to the University of Utah.
At that time a program for the diagnosis and management of patients with pulmonary hypertension did not exist and Dr Elliott successfully negotiated time and resources to launch one. At about this time, the NIH registry was forming and his center in Utah became one of the enrolling sites. At this time, he also initiated research in diagnosing, preventing, and treating venous thromboembolism-research he is still conducting.
A broad spectrum of service characterizes his career, including a long history of service to the NIH, the American Thoracic Society, the American College of Physicians, the American Heart Association, and PHA. At PHA, Dr Elliott served as the second chair of what is now the Scientific Leadership Council, where he continues to serve the association, and chaired the Scientific Sessions at the 2006 Conference. In addition to his award as Outstanding Physician at the 2006 conference, he has won numerous teaching awards for his work with medical and graduate students, residents, and fellows. In the publishing arena, he has over 90 peer-reviewed publications and numerous book chapters and presentations.
The success of the recent Scientific Sessions was largely due to the organizational efforts led by Dr Elliott. "The sessions are an opportunity to get folks with a real interest in PH in one room. This includes basic scientists, clinical scientists, and clinicians and we have had the opportunity to bring investigators of the highest level from outside the pulmonary hypertension community to the meeting to stimulate us with new ideas and methods for addressing unanswered questions in pulmonary hypertension." He also believes that the sessions offer a unique opportunity to basic scientists to interact with patients and families at the larger Conference, "and put a face to this disease. I am always inspired and I think that this interaction inspires all of us to go back to the clinic and the lab and work as hard as we can."
Esteemed colleagues in the PH medical community testify to the energy and enthusiasm of Dr Elliott. They talk about his tremendous integrity, approachability, how balanced he is in his deliberation and calming in his discussion with patients about a dreaded illness. "I think we all rely on Greg to have the final word that brings balanced reason to any controversial issue," says Michael McGoon, MD. Nicholas Hill, MD, adds: "I've long been an admirer of Greg. He embodies many of Greg Elliott, MD (continued on page 5) Advances in Pulmonary Hypertension 5
the traits that we all should aspire to." And colleague David Badesch, MD, said: "I have always considered Greg to be a close friend, mentor, and advisor and never hesitate to call him with the toughest questions that I face." Robyn Barst, MD, calls him "a true mensch."
PHA staff also echo these expressions of gratitude.
"PHA has always been an organization of patients, family members, and medical professionals. In that it is unusual and, like anything unusual, often hard for many to understand. As the second chair of PHA's Scientific Leadership Council, Greg Elliott not only understood the possibilities in such a unique partnership but helped to move them from the abstract to a concrete tool for changing the history of this illness," said Rino Aldrighetti, President of PHA.
Profile -Greg Elliott, MD
(continued from page 4)
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PHA is pleased to introduce the Spanish version of its popular resource tool
The Patient's Survival Guide is the most comprehensive resource available to PH patients. Written by PH patient Gayle Boyer Hayes and medically reviewed by Dr. Ron Oudiz, it provides information about the disease, the risks and benefits of various treatments, information about diet, and even includes a chapter about children with PH. It is an excellent resource not only for patients but also for family members or caregivers, who are not familiar with the disease. Many PH treating physicians also use it in their practices as a helpful reference tool. Due to an increasing demand for Spanish language materials this wonderful tool has been translated into Spanish by Dr. Tomas Pulido & Dr. Julio Sandoval of the National Cardiology Institute in Mexico City.
We thank them for their hard work & dedication which made this project possible. 
Order your copy today!
Copies of the Spanish or English versions of the
A Cornerstone of Oral Therapy
In pulmonary arterial hypertension (PAH) WHO Class III or IV
93% and 84% of patients in the 2 Tracleer pivotal trials and their open-label extensions (N=235)
were still alive at 1 year and 2 years, respectively, after the start of treatment with Tracleer. 2 I Without a control group, these data must be interpreted cautiously 2 I These estimates may be influenced by the presence of epoprostenol treatment, which was administered to 43 of the 235 patients 2 I Patients in the Tracleer trials may have also been receiving vasodilators (calcium channel blockers or ACE inhibitors), digoxin, anticoagulants, and/or diuretics 2
Liver and pregnancy warnings
I Requires attention to two significant concerns: Potential for serious liver injuryLiver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects-Pregnancy must be excluded and prevented by two forms of birth control; monthly pregnancy tests should be obtained
Prescribed to over 30,000 patients Please see brief summary of prescribing information and full reference list on following page. 6  0  12  24  18  225  235  219  206  146 Months Patients at risk % of event-free patients should be considered. Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER ® is initiated to see whether the statin dose needs adjustment. Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively. Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose, and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan-and placebo-treated patients. Digoxin, Nimodipine and Losartan: Bosentan has been shown to have no pharmacokinetic interactions with digoxin and nimodipine, and losartan has no effect on plasma levels of bosentan. Sildenafil: In healthy subjects, co-administration of multiple doses of 125 mg b.i.d bosentan and 80 mg t.i.d. sildenafil resulted in a reduction of sildenafil plasma concentrations by 63% and increased bosentan plasma concentrations by 50%. A dose adjustment of neither drug is necessary. This recommendation holds true when sildenafil is used for the treatment of pulmonary arterial hypertension or erectile dysfunction. Carcinogenesis, Mutagenesis, Impairment of Fertility: Two years of dietary administration of bosentan to mice produced an increased incidence of hepatocellular adenomas and carcinomas in males at doses about 8 times the maximum recommended human dose [MRHD] of 125 mg b.i.d., on a mg/m 2 basis. In the same study, doses greater than about 32 times the MRHD were associated with an increased incidence of colon adenomas in both males and females. In rats, dietary administration of bosentan for two years was associated with an increased incidence of brain astrocytomas in males at doses about 16 times the MRHD. Impairment of Fertility/Testicular Function: Many endothelin receptor antagonists have profound effects on the histology and function of the testes in animals. These drugs have been shown to induce atrophy of the seminiferous tubules of the testes and to reduce sperm counts and male fertility in rats when administered for longer than 10 weeks. Where studied, testicular tubular atrophy and decreases in male fertility observed with endothelin receptor antagonists appear irreversible. In fertility studies in which male and female rats were treated with bosentan at oral doses of up to 50 times the MRHD on a mg/m 2 basis, no effects on sperm count, sperm motility, mating performance or fertility were observed. An increased incidence of testicular tubular atrophy was observed in rats given bosentan orally at doses as low as about 4 times the MRHD for two years but not at doses as high as about 50 times the MRHD for 6 months. An increased incidence of tubular atrophy was not observed in mice treated for 2 years at doses up to about 75 times the MRHD or in dogs treated up to 12 months at doses up to about 50 times the MRHD. There are no data on the effects of bosentan or other endothelin receptor antagonists on testicular function in man. Pregnancy, Teratogenic Effects: Category X SPECIAL POPULATIONS: Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, breastfeeding while taking TRACLEER ® is not recommended. Pediatric Use: Safety and efficacy in pediatric patients have not been established. Use in Elderly Patients: Clinical experience with TRACLEER ® in subjects aged 65 or older has not included a sufficient number of such subjects to identify a difference in response between elderly and younger patients. ADVERSE REACTIONS: Safety data on bosentan were obtained from 12 clinical studies (8 placebo-controlled and 4 open-label) in 777 patients with pulmonary arterial hypertension, and other diseases. Treatment discontinuations due to adverse events other than those related to pulmonary hypertension during the clinical trials in patients with pulmonary arterial hypertension were more frequent on bosentan (5%; 8/165 patients) than on placebo (3%; 2/80 patients). In this database the only cause of discontinuations > 1%, and occurring more often on bosentan was abnormal liver function. In placebo-controlled studies of bosentan in pulmonary arterial hypertension and for other diseases (primarily chronic heart failure), a total of 677 patients were treated with bosentan at daily doses ranging from 100 mg to 2000 mg and 288 patients were treated with placebo. The duration of treatment ranged from 4 weeks to 6 months. For the adverse drug reactions that occurred in * 3% of bosentan-treated patients, the only ones that occurred more frequently on bosentan than on placebo (* 2% difference) were headache (16% vs. 13%), flushing (7% vs. 2%), abnormal hepatic function (6% vs. 2%), leg edema (5% vs. 1%), and anemia (3% vs. 1%). Additional adverse reactions that occurred in > 3% of bosentan-treated pulmonary arterial hypertension patients were: nasopharyngitis (11% vs. 8%), hypotension (7% vs. 4%), palpitations (5% vs. 1%), dyspepsia (4% vs. 0%), edema (4% vs. 3%), fatigue (4% vs. 1%), and pruritus (4% vs. 0%). Post-marketing experience: hypersensitivity, rash, angiodema. Special Considerations: Patients with Congestive Heart Failure (CHF): Based on the results of a pair of studies with 1613 subjects, bosentan is not effective in the treatment of CHF with left ventricular dysfunction. OVERDOSAGE: Bosentan has been given as a single dose of up to 2400 mg in normal volunteers, or up to 2000 mg/day for 2 months in patients, without any major clinical consequences. The most common side effect was headache of mild to moderate intensity. In the cyclosporine A interaction study, in which doses of 500 and 1000 mg b.i.d. of bosentan were given concomitantly with cyclosporine A, trough plasma concentrations of bosentan increased 30-fold, resulting in severe headache, nausea, and vomiting, but no serious adverse events. Mild decreases in blood pressure and increases in heart rate were observed. There is no specific experience of overdosage with bosentan beyond the doses described above. Give your patients with pulmonary arterial hypertension NYHA Class II-IV…
Tracleer Provides 2-Year Follow-up Data
The power of continuously infused prostacyclin with:
• No ice packs REMODULIN is now the first and only prostacyclin: "…indicated to diminish the rate of clinical deterioration in patients requiring transition from Flolan®; the risks and benefits of each drug should be carefully considered prior to transition"
• REMODULIN is also indicated as a continuous subcutaneous (SC) infusion or intravenous (IV) infusion (for those not able to tolerate an SC infusion) for the treatment of pulmonary arterial hypertension in patients with New York Heart Association (NYHA) Class II-IV symptoms to diminish symptoms associated with exercise
IMPORTANT SAFET Y INFORMATION:
REMODULIN is contraindicated in patients with hypersensitivity to REMODULIN, its ingredients, or similar drugs. The most common side effects of REMODULIN included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of REMODULIN. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilation, and edema. REMODULIN is a potent vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. REMODULIN may increase the risk of bleeding, particularly in patients on anticoagulants. Abrupt withdrawal or sudden large reductions in dosage of REMODULIN may result in worsening of PAH symptoms.
N E W
For important safety and other information, please see brief summary of full prescribing information on the back of this page.
REMODULIN is a registered trademark of United Therapeutics Corporation.
Flolan is a registered trademark of GlaxoSmithKline.
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REMODULIN ® (treprostinil sodium) Injection BRIEF SUMMARY
The following is a brief summary of the full prescribing information on Remodulin (treprostinil sodium) Injection. Please review the full prescribing information prior to prescribing Remodulin.
INDICATIONS AND USAGE
Remodulin ® is indicated as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Remodulin is indicated to diminish the rate of clinical deterioration in patients requiring transition from Flolan ® ; the risks and benefits of each drug should be carefully considered prior to transition.
DESCRIPTION
Remodulin ® (treprostinil sodium) Injection is a sterile sodium salt supplied in 20 mL vials in four strengths, containing 1 mg/mL, 2.5 mg/mL, 5 mg/mL or 10 mg/mL of treprostinil. Each mL also contains 5.3 mg sodium chloride (except for the 10 mg/mL strength which contains 4.0 mg sodium chloride), 3.0 mg metacresol, 6.3 mg sodium citrate, and water for injection.
CONTRAINDICATIONS
Remodulin is contraindicated in patients with known hypersensitivity to the drug or to structurally related compounds.
WARNINGS
Remodulin is indicated for subcutaneous or intravenous use only.
PRECAUTIONS
General
Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH. Remodulin is a potent pulmonary and systemic vasodilator. Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care. Therapy with Remodulin may be used for prolonged periods, and the patient's ability to administer Remodulin and care for an infusion system should be carefully considered. Dose should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic effects or for unacceptable infusion site symptoms. Abrupt withdrawal or sudden large reductions in dosage of Remodulin may result in worsening of PAH symptoms and should be avoided.
Information for Patients
Patients receiving Remodulin should be given the following information: Remodulin is infused continuously through a subcutaneous or surgically placed indwelling central venous catheter, via an infusion pump. Therapy with Remodulin will be needed for prolonged periods, possibly years, and the patient's ability to accept and care for a catheter and to use an infusion pump should be carefully considered. In order to reduce the risk of infection, aseptic technique must be used in the preparation and administration of Remodulin. Additionally, patients should be aware that subsequent disease management may require the initiation of an alternative intravenous prostacyclin therapy, Flolan ® (epoprostenol sodium).
Drug Interactions
Reduction in blood pressure caused by Remodulin may be exacerbated by drugs that by themselves alter blood pressure, such as diuretics, antihypertensive agents, or vasodilators. Since Remodulin inhibits platelet aggregation, there is also a potential for increased risk of bleeding, particularly among patients maintained on anticoagulants. During clinical trials, Remodulin was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal anti-inflammatories, opioids, corticosteroids, and other medications. Remodulin has not been studied in conjunction with Flolan or Tracleer ® (bosentan).
Effect of Other Drugs on Remodulin
In vivo studies: Acetaminophen -Analgesic doses of acetaminophen, 1000 mg every 6 hours for seven doses, did not affect the pharmacokinetics of Remodulin, at a subcutaneous infusion rate of 15 ng/kg/min.
Effect of Remodulin on Other Drugs
In vitro studies: Remodulin did not significantly affect the plasma protein binding of normally observed concentrations of digoxin or warfarin. In vivo studies: Warfarin -Remodulin does not affect the pharmacokinetics or pharmacodynamics of warfarin. The pharmacokinetics of R-and S-warfarin and the INR in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous Remodulin at an infusion rate of 10 ng/kg/min.
Hepatic and Renal Impairment
Caution should be used in patients with hepatic or renal impairment.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies have not been performed to evaluate the carcinogenic potential of treprostinil. In vitro and in vivo genetic toxicology studies did not demonstrate any mutagenic or clastogenic effects of treprostinil. Treprostinil sodium did not affect fertility or mating performance of male or female rats given continuous subcutaneous infusions at rates of up to 450 ng treprostinil/kg/min [about 59 times the recommended starting human rate of infusion (1.25 ng/kg/min) and about 8 times the average rate (9.3 ng/kg/min) achieved in clinical trials, on a ng/m 2 basis]. In this study, males were dosed from 10 weeks prior to mating and through the 2-week mating period. Females were dosed from 2 weeks prior to mating until gestational day 6.
Pregnancy
Pregnancy Category B -In pregnant rats, continuous subcutaneous infusions of treprostinil sodium during organogenesis and late gestational development, at rates as high as 900 ng treprostinil/kg/min (about 117 times the starting human rate of infusion, on a ng/m 2 basis and about 16 times the average rate achieved in clinical trials), resulted in no evidence of harm to the fetus. In pregnant rabbits, effects of continuous subcutaneous infusions of treprostinil during organogenesis were limited to an increased incidence of fetal skeletal variations (bilateral full rib or right rudimentary rib on lumbar 1) associated with maternal toxicity (reduction in body weight and food consumption) at an infusion rate of 150 ng treprostinil/kg/min (about 41 times the starting human rate of infusion, on a ng/m 2 basis, and 5 times the average rate used in clinical trials). In rats, continuous subcutaneous infusion of treprostinil from implantation to the end of lactation, at rates of up to 450 ng treprostinil/kg/min, did not affect the growth and development of offspring. Because animal reproduction studies are not always predictive of human response, Remodulin should be used during pregnancy only if clearly needed.
Labor and delivery
No treprostinil sodium treatment-related effects on labor and delivery were seen in animal studies. The effect of treprostinil sodium on labor and delivery in humans is unknown.
Nursing mothers
It is not known whether treprostinil is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, caution should be exercised when Remodulin is administered to nursing women.
Pediatric use
Safety and effectiveness in pediatric patients have not been established. Clinical studies of Remodulin did not include sufficient numbers of patients aged ≤16 years to determine whether they respond differently from older patients. In general, dose selection should be cautious.
Geriatric use
Clinical studies of Remodulin did not include sufficient numbers of patients aged 65
and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Reported adverse events (at least 3%) are included except those too general to be informative, and those not plausibly attributable to the use of the drug, because they were associated with the condition being treated or are very common in the treated population.
ADVERSE REACTIONS
Adverse Events Attributable to the Drug Delivery System
In controlled studies of Remodulin administered subcutaneously, there were no reports of infection related to the drug delivery system. There were 187 infusion system complications reported in 28% of patients (23% Remodulin, 33% placebo); 173 (93%) were pump related and 14 (7%) related to the infusion set. Eight of these patients (4 Remodulin, 4 Placebo) reported non-serious adverse events resulting from infusion system complications. Adverse events resulting from problems with the delivery systems were typically related to either symptoms of excess Remodulin (e.g., nausea) or return of PAH symptoms (e.g., dyspnea). These events were generally resolved by correcting the delivery system pump or infusion set problem such as replacing the syringe or battery, reprogramming the pump, or straightening a crimped infusion line. Adverse events resulting from problems with the delivery system did not lead to clinical instability or rapid deterioration. There are no controlled clinical studies with Remodulin administered intravenously. Among the subjects (n=38) treated for 12-weeks in an open-label study, 2 patients had either line infections or sepsis. Other events potentially related to the mode of infusion include arm swelling, paresthesias, hematoma and pain.
OVERDOSAGE
Signs and symptoms of overdose with Remodulin during clinical trials are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of Remodulin.
In controlled clinical trials, seven patients received some level of overdose and in open-label follow-on treatment seven additional patients received an overdose; these occurrences resulted from accidental bolus administration of Remodulin, errors in pump programmed rate of administration, and prescription of an incorrect dose. In only two cases did excess delivery of Remodulin produce an event of substantial hemodynamic concern (hypotension, near-syncope). One pediatric patient was accidentally administered 7.5 mg of Remodulin via a central venous catheter. Symptoms included flushing, headache, nausea, vomiting, hypotension and seizure-like activity with loss of consciousness lasting several minutes. The patient subsequently recovered.
DOSAGE AND ADMINISTRATION
Remodulin ® is supplied in 20 mL vials in concentrations of 1 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL. Remodulin can be administered as supplied or diluted for intravenous infusion with Sterile Water for Injection or 0.9% Sodium Chloride Injection prior to administration.
Initial Dose for Patients New to Prostacyclin Infusion Therapy
Remodulin is administered by continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central intravenous line if the subcutaneous route is not tolerated, because of severe site pain or reaction. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min.
Dosage Adjustments
The goal of chronic dosage adjustments is to establish a dose at which PAH symptoms are improved, while minimizing excessive pharmacologic effects of Remodulin (headache, nausea, emesis, restlessness, anxiety and infusion site pain or reaction). The infusion rate should be increased in increments of no more than 1.25 ng/kg/min per week for the first four weeks and then no more than 2.5 ng/kg/min per week for the remaining duration of infusion, depending on clinical response. There is little experience with doses >40 ng/kg/min. Abrupt cessation of infusion should be avoided (see PRECAUTIONS).
Administration
Subcutaneous Infusion
Remodulin is administered subcutaneously by continuous infusion, via a self-inserted subcutaneous catheter, using an infusion pump designed for subcutaneous drug delivery. To avoid potential interruptions in drug delivery, the patient must have immediate access to a backup infusion pump and subcutaneous infusion sets. The ambulatory infusion pump used to administer Remodulin should: (1) 
Intravenous Infusion
Remodulin must be diluted with either Sterile Water for Injection or 0.9% Sodium Chloride Injection and is administered intravenously by continuous infusion, via a surgically placed indwelling central venous catheter, using an infusion pump designed for intravenous drug delivery. To avoid potential interruptions in drug delivery, the patient must have immediate access to a backup infusion pump and infusion sets. The ambulatory infusion pump used to administer Remodulin should: (1) be small and lightweight, (2) have occlusion/no delivery, low battery, programming error and motor malfunction alarms, (3) have delivery accuracy of ±6% or better of the hourly dose, and (4) be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene or glass. Diluted Remodulin has been shown to be stable at ambient temperature for up to 48 hours at concentrations as low as 0.004 mg/mL (4,000 ng/mL). When using an appropriate infusion pump and reservoir, a predetermined intravenous infusion rate should first be selected to allow for a desired infusion period length of up to 48 hours between system changeovers. Typical intravenous infusion system reservoirs have volumes of 50 or 100 mL. With this selected Intravenous Infusion Rate (mL/hr) and the patient's Dose (ng/kg/min) and Weight (kg), the Diluted Intravenous Remodulin Concentration (mg/mL) can be calculated using the following formula:
The Amount of Remodulin Injection needed to make the required Diluted Intravenous Remodulin Concentration for the given reservoir size can then be calculated using the following formula:
Step 1 Dose
Diluted Intravenous
Step 2 Remodulin Concentration Total Volume of Amount of (mg/mL)
Diluted Remodulin Remodulin = x Solution in Reservoir Injection
Remodulin Vial Strength (mL) (mL) (mg/mL)
The calculated amount of Remodulin Injection is then added to the reservoir along with the sufficient volume of diluent (Sterile Water for Injection or 0.9% Sodium Chloride Injection) to achieve the desired total volume in the reservoir.
In patients requiring transition from Flolan:
Transition from Flolan to Remodulin is accomplished by initiating the infusion of Remodulin and increasing it, while simultaneously reducing the dose of intravenous Flolan. The transition to Remodulin should take place in a hospital with constant observation of response (e.g., walk distance and signs and symptoms of disease progression). During the transition, Remodulin is initiated at a recommended dose of 10% of the current Flolan dose, and then escalated as the Flolan dose is decreased (see table below for recommended dose titrations).
Patients are individually titrated to a dose that allows transition from Flolan therapy to Remodulin while balancing prostacyclin-limiting adverse events. Increases in the patient's symptoms of PAH should be first treated with increases in the dose of Remodulin. Side effects normally associated with prostacyclin and prostacyclin analogs are to be first treated by decreasing the dose of Flolan.
Recommended Transition Dose Changes
Step Flolan Dose Remodulin Dose 
HOW SUPPLIED
Remodulin ® is supplied in 20 mL multi-use vials at concentrations of 1 mg/mL, 2.5 mg/mL, 5 mg/mL, and 10 mg/mL treprostinil, as sterile solutions in water for injection, individually packaged in a carton. Unopened vials of Remodulin are stable until the date indicated when stored at 15 to 2°C (59 to 77°F). Store at 25°C (77°F), with excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
During use, a single reservoir (syringe) of undiluted Remodulin can be administered up to 72 hours at 37°C. Diluted Remodulin Solution can be administered up to 48 hours at 37°C when diluted to concentrations as low as 0.004 mg/mL in Sterile Water for Injection or 0.9% Sodium Chloride Injection. A single vial of Remodulin should be used for no more than 30 days after the initial introduction into the vial.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If either particulate matter or discoloration is noted, Remodulin should not be administered. Abundant research over the past decade has implicated inflammation in several facets of systemic vascular disease. Initially, these data focused on early atherogenesis as well as the conversion of stable to unstable vascular lesions (ie, atherosclerotic plaque rupture). It is now clear that inflammation plays a major role in the risk of myocardial infarction and stroke. It also plays a role in the prognosis of patients with heart failure. The clinical expression of these observations has been the adoption of high sensitivity C-reactive protein (hsCRP) as a clinical marker for the risk of cardiovascular disease. 1, 2 CRP is a circulating pentraxin important in innate immunity and can be measured in the plasma as a marker of inflammation. CRP is made in the liver as an acute phase response protein but is also made in diseased vascular smooth muscle cells, particularly in atherosclerotic vessels. Thus, CRP may not only serve as a marker for cardiovascular disease risk but also suggests the important role of inflammation in vascular disease. This relationship between inflammation and vascular disease also helps to explain why patients with divergent diseases including systemic inflammatory diseases (ie, systemic lupus erythematosus), arthritis, and periodontal disease have higher risk of cardiovascular disease. This also highlights that inflammation from a variety of causes may lead to vascular disease. 1, 2 HsCRP levels < 1, 1 to 3, and > 3 mg/L have repeatedly been shown to add independent prognostic information on the risk of myocardial infarction, stroke, and cardiovascular death. At all levels of low-density lipoprotein cholesterol (LDL-C), increased hsCRP levels are associated with increased risk. Similar results are present in patients with the metabolic syndrome. The addition of hsCRP to global risk prediction algorithms for cardiovascular disease such as the Framingham Risk Score also assists in identifying patients with highest risk. While these levels are grouped into low, moderate, and high risk based on the above levels, indeed the highest levels confer the highest risk. 2, 3 From a population perspective, the proportion of vascular disease attributable to inflammation appears to be as large as that attributable to elevated cholesterol. This observation has had importance for drug development and many novel anti-inflammatory compounds are now being evaluated as potential methods to inhibit atherosclerotic progression. [1] [2] [3] These inflammatory processes, however, extend beyond the coronary and cerebral circulations and appear to have an impact on all portions of the systemic vasculature. With regard to peripheral arterial disease, for example, elevated levels of several cytokines and hsCRP appear to be of similar importance as smoking for disease development and progression. Recent data have also implicated inflammation as a crucial process in vascular hypertension, and certain antihypertensive agents appear to preferentially impact upon this process. 1, 2 To date, the greatest clinical impact of the inflammatory hypothesis of atherosclerosis has been an improved understanding and utilization of statin therapy. Statins lower CRP levels in addition to lowering LDL-C, and data from both primary and secondary prevention trials indicate that the benefit of statin therapy is greater among those with high CRP levels. Further, in the setting of acute ischemia, achieving very low levels of LDL-C (< 70 mg/dL) and low levels of hsCRP (< 2 mg/L) has proven to be important for clinical outcomes. Thus, data now support the concept of "dual targeting," such that monitoring inflammation as well as cholesterol is recognized as an important method to improve long-term patient outcomes. Currently, trials are under way that target persons with LDL less than 130 but CRP greater than 2, subjects who would not ordinarily qualify for statin therapy, in a primary cardiovascular disease prevention strategy. 3, 4 Preliminary reports suggest that CRP is elevated in patients with pulmonary hypertension and a large prospective study is currently under way to define this relationship further. Several lines of evidence suggest the importance of inflammation in the pathogenesis of pulmonary arterial hypertension and improved understanding of inflammation is likely to be of importance in understanding the pathogenesis of pulmonary hypertension, especially since many disorders associated with pulmonary hypertension are associated with several inflammatory pathways.
Rx only
5-7
References: During the last few years, magnetic resonance imaging (MRI) has emerged as a modality with enormous potential for the noninvasive evaluation of pulmonary hypertension (PH). It does not involve ionizing radiation or nephrotoxic contrast agents (unlike computed tomography or nuclear techniques) and does not have imaging window limitations (as is the case with echocardiography). These MRI techniques are being applied to assessment of the vascular structure as well as the myocardium.
High resolution MRI and magnetic resonance angiography (MRA) have been used in the imaging of atherothrombotic disease with the advantage of imaging the entire vessel wall, not just the luminal surface as is possible with conventional angiography. The combined use of these imaging modalities has been used to image the aorta and cerebral circulations to characterize plaque size and structure and ultimately regression after interventions such as statin therapy. In the peripheral arteries, MRI techniques have been used to assess response and complications of balloon angioplasty of stenotic lesions. These imaging techniques may also allow for high fidelity imaging of the coronary circulation as well. 1 The fidelity of MRI techniques to assess the vasculature may also be further enhanced by the use of cell-specific contrast agents that identify a specific cell type in the vessel wall. A wide range of cellular and molecular targets including adhesion molecules, inflammatory cells, apopotic cells, matrix proteins, angiogenic proteins, and thrombosisrelated proteins have been suggested to further characterize vascular lesions. 1 Evolving MRI techniques may also allow for the assessment of flow through a vessel. By tagging the blood cells as they flow through a specific vessel, these techniques would allow for assessment of flow patterns in healthy as well as diseased vessels. 1 MRI is rapidly evolving as a comprehensive approach to evaluating both the structure and function of the heart. This has obvious implications in the identification of left-sided cardiac disease and congenital heart lesions in the pathogenesis of PH. MRI of the right ventricle (RV) can assess mass, volume, and contractility, yielding accurate measurements that do not depend on geometrical assumptions and that correlate strongly with pulmonary pressures obtained by conventional modalities such as echo and right heart catheterization. Quantification of the anomalous interventricular septal curvature associated with RV pressure overload is highly accurate for the determination of systolic pulmonary pressure and the detection of PH. 2, 3 Contrast-enhanced magnetic resonance angiography (MRA) can be used to visualize the complete pulmonary tree and may be useful in detecting the typical changes of chronic thromboembolic PH. 4, 5 Time-resolved MRA additionally provides physiologic information of lung circulatory physiology. Phase-contrast imaging can be employed for accurate flow quantifications and calculations of QP/QS ratios. 6 In addition, the flow profile in the complete cross-section of the pulmonary artery or its branches can be noninvasively evaluated, and various parameters derived from these measurements correlate with the degree of hemodynamic impairment. 6 MRI techniques have also been used to determine the extent of fibrotic remodeling following myocardial infarction. MRI may also be useful in determining the extent of myocardium that is currently ischemic or at risk of ischemia. This may be important in the identification of exerciseinduced PH. Both of these may have important roles in determining the degree of RV impairment in PH as MRI demonstrates the presence of fibrosis in the insertion sites of the RV in the interventricular septum, a finding correlated with the severity of PH. 7, 8 Recent advances in interventional MRI, allowing for the simultaneous quantification of pulmonary pressures with the use of MRI-compatible catheters, promise to further increase the utility of this versatile technique.
MRI has much promise in the further structural and functional characterization of the pulmonary circulation and will likely evolve as an additional important diagnostic and prognostic tool. Results. The size of the population expanded predictably as the inclusion criteria were loosened. The most strictly defined group (A) had only 30 pts as shown in Table 1 . Group B (56 pts) represents the usual inclusion criteria of clinical drug studies. Groups C-E include pts in whom the clinical impression was that their diagnoses were IPAH despite some criteria either missing or falling outside usual limits. RVSP, PCWP and TLC remained quite similar among groups even as those criteria were omitted or altered, among those patients in whom measurements were made. SBP increased when a value <140 mm Hg was eliminated as a criterion. Medical treatment was examined in the most strictly and liberally defined groups (A and E: Table 2 ). The overall medical profile of each group was similar.
Diagnostic Criteria for Idiopathic
Comments and Conclusions.
The population diagnosed with and treated for IPAH at this referral center is much larger than, but not dissimilar from, the population defined by conventional hemodynamic, pulmonary function and echocardiographic criteria. Many patients appear to be treated by extrapolation of data from a more narrowly defined population. It is untested whether these patients derive the same benefit from PH drug treatments. We suggest that future clinical drug studies of IPAH be expanded beyond the current narrow definition of IPAH. Methods. In 16 dogs, right atrial (RA) and ventricular (RV) pressure and volume (conductance catheter) were simultaneously recorded after 3 months of progressive pulmonary artery (PA) banding. Diltiazem was given at 10 mg/h with the PA constricted (CCB non-responder). Responders were then created by releasing the PA band to unload the ventricle. RA and RV contractility and diastolic stiffness (slope of end-systolic and end-diastolic PV relations) were calculated and RA reservoir and conduit function were quantified as RA inflow with the tricuspid valve closed versus open, respectively. Results. With CCB, RA contractility (P < .03) and cardiac output (P < .004) decreased in non-responders while RV pressure and contractility were unchanged (Table) . After PA band release, the RA became less distensible, causing a shift from reservoir to conduit function (P < .001) and the contractility in both chambers decreased (P < .007). RA and RV diastolic function in non-responders and responders was not affected by CCB. Conclusions. CCB did not impact RV function in nonresponders, but significantly impaired RA contractility and cardiac output. In responders, afterload fell substantially to maintain cardiac output despite a decline in the normal RA and RV hyperdynamic contractile response to CPH. Thus, clinical use of CCB in CPH should be restricted to documented responders. About 50% of patients with familial PH possess identifiable exon or intron/exon boundry mutations in bone morphogenetic protein receptor type 2 (BMPR2). These mutations are not just synonymous substitutions, but include missense, nonsense, frameshift, or donor/acceptor splice mutations that can alter the structure of the receptor and damage its function. 1, 2 These mutations are easily detected by sequencing the exons of BMPR2. There are 13 exons in BMPR2 comprising about 3000 bases of sequencing results. About 150 mutations have been found in persons with familial and idiopathic pulmonary arterial hypertension (PAH). 1 The total gene is 180,000 kilobases long, mostly introns and so sequencing the whole gene is an expensive and laborious process. When a mutation in a family has been identified, it is relatively easy to perform exon specific sequence analysis and to test other family members. However, if the mutation is not known, full sequencing of all exons is needed.
*P < .05 versus baseline
Other strategies have been developed to detect mutations. As with some other genetic diseases, about 15% to 20% of BMPR2 mutations include gross rearrangements of the gene that result in exon duplications and deletions. 3 These mutations cannot be detected by routine exon-byexon sequence analysis of BMPR2 but rather require Southern Blot analysis for detection, and BMPR2 messenger ribonucleic acid (mRNA) analysis for confirmation and specific identification of the mutation.
Trembath et al 4 have shown that PAH is also associated with mutations in another transforming growth factor beta (TGFb) receptor family member, the activin-like kinase (Alk1) and its cofactor, endoglin. 4 Mutations in Alk1 are the cause of hereditary-hemorrhagic telangiectasia (HHT), a vascular disease leading to abnormal arteriovenous malformations. Some patients with HHT develop PAH, and some persons with Alk1 mutations develop PAH without the classic lesions of HHT. We do not know the actual prevalence of Alk1 mutations in a population of PAH patients but think that it is less than 5%. In a full screening study of PAH populations or patients with idiopathic PAH undergoing genetic testing, mutations in Alk1 would need to be excluded to be complete.
Somatic mutations in arterial lesions in the lung of PAH patients have been found, but a recent examination by Machado et al 5 failed to reveal loss of heterozygosity of BMPR2 in microdissected lesions in 7 PAH patients and microsatellite instability in only 1 of 37 lesions. Thus, it seems unlikely that somatic transformation of BMPR2 in the pulmonary arterioles causes PAH, although this work only excludes mismatched repair genes that cause microsatellite instability and large deletions of chromosomal material. This work also does not exclude somatic transformation of genes other than BMPR2 that might be involved in pathogenesis of PAH.
Finally, because BMPR2 mutations only exhibit about a 20% penetrance-80% of persons with a mutation will remain clinically normal-there must be other environmental factors or modifying genes that confer either protection or risk for disease. 6 The search for such genes is in its infancy, and none has been clearly identified. The best-studied gene that is likely to be involved in disease is the serotonin transporter, which regulates cellular uptake of serotonin, a known vasoconstrictor and mitogenic protein. 7 Multiple • 15% to 25% of "sporadic" idiopathic PAH cases have BMPR2 mutations
• Alk1/endoglin mutations (HHT) in < 5%
• About 20% of persons with mutations get PAH
• There must be modifying genes and other influences that trigger disease BMPR2 = bone morphogenetic protein receptor, type 2; HHT = hereditary haemorrhagic telangiectasia; PAH = pulmonary arterial hypertension.
22 Advances in Pulmonary Hypertension potential approaches to detection of modifying genes including gene expression microarray, proteomics, genetic association studies in PAH patients and whole genome microsatellite searches may help to identify shared haplotypes in PAH patients in the future.
A difficult problem to grasp is the prevalence and role of BMPR2 mutations in idiopathic PAH ( Table 2) . Idiopathic PAH is genetically defined as an isolated occurrence within a family with no known other affected members. The term "idiopathic" is more certain when a search for known PAH genes is negative in an individual with idiopathic PAH. It seems contradictory that up to 25% of patients with socalled idiopathic PAH have been found to have BMPR2 mutations when tested. 8 Why are more members of this person's family not affected?
In the minority of cases the answer is that some of the mutations in BMPR2 are de novo, and thus the patient is the first person in a new potential family with familial PAH. De novo mutations comprise about 25% of the group of idiopathic PAH patients that are found to be BMPR2 positive. The second explanation has to do with the relatively low penetrance (20%) of clinical disease in persons with BMPR2 mutations. If a person with a BMPR2 mutation has a child, the a priori risk that the child will inherit the mutated allele is 50%. Thus, there is only a 0.5 X 0.2 or a 10% chance of the offspring developing clinical disease. If this offspring were to have children, then the likelihood of clinical disease would be 5% in each child. Thus, the statistical likelihood that a BMPR2 mutation will become detected clinically in a family over several generations is estimated to be only about 20% to 40%, depending on how many children and how many generations of children are counted. Thus, some patients with idiopathic PAH may actually belong to families with mutations in BMPR2 but with very low penetrance of disease.
Interestingly, BMPR2 mutations are not limited strictly to patients with PAH ( Table 3) . BMPR2 mutations have been found in about 6% of subjects with congenital heart disease and in several families with pulmonary veno-occlusive disease. This highlights the importance of the BMPR2 receptor in fetal cardiac development and the knowledge that the pulmonary veins can be affected by a similar disease process as the arterioles.
In summary, progress has been significant in the past year toward delineating the role of BMPR2 mutations in familial and idiopathic PAH, in congenital heart disease, and pulmonary veno-occlusive disease. The extent of BMPR2 mutations in the total population of patients with PAH is likely to be very large, because of underestimates of prevalence due to low penetrance. Genetic testing is now available at a few centers, and because the realm of BMPR2 mutations is a mix of exonic mutations and gross rearrangements, this testing is necessarily complex in order to completely assess for heritable disease traits. Future work will include studies of the whole genome and large populations of patients for detection of relevant modifying genes.
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Glossary of Words and Terms Used in this Paper
Alk1/Endoglin: A receptor complex of the TGFb family that, when mutated, results in hereditary hemorrhagic telangiectasia and, occasionally, PAH.
BMPR2: A receptor that is part of the TGFb (see below) family of receptors involved in growth and repair.
Exon: A segment of DNA that is transcribed to mRNA and ultimately translated into a protein product. Most genes have multiple exons.
Gene microarray: A technique for measuring the products of transcription of deoxyribonucleic acid (DNA) to ribonucleic acid (RNA) and potentially, therefore, translation to final protein of a cell or tissue. 
Intron: A segment of DNA that is not transcribed. Formerly thought to be inactive, introns are involved in the orderly sequence of gene transcription.
Microsatellite: A sequence of DNA composed of repeating nucleotides, such as cytosine-adenine-cytosine. These can be used as genetic markers because they are inherited intact. When the repeats become longer in certain genes they can be associated with disease.
Missense, nonsense, and frameshift mutations: Missense causes a different amino acid to be substituted in a protein, nonsense causes the gene product to be truncated, and frameshift involves making all subsequent transcription wrong by changing the reading of all subsequent DNA code in a gene.
Penetrance: The mathematical likelihood that a mutation will result in clinical disease.
Somatic mutations: These occur in organ cells rather than sex cells. In gastrointestinal tumors, somatic mutations are very important for transformation from normal to disease.
Southern blot: A technique to look at all the DNA of an area of interest including exons and introns.
Splice mutations: At the borders between exons and introns are DNA sequences that allow the mRNA that is transcribed from exons to be spliced together properly. Splice mutations can result in exons being deleted, duplicated, or put in the wrong order.
TGFb: A secreted protein that is involved in growth and repair of tissues. It is part of a large family of proteins.
Each program will also include separate medical education sessions for PAH patients and families
The continuing medical education (CME) course is designed for healthcare providers who manage patients with or at risk for PAH This activity has been approved for AMA PRA Category 
STATEMENT OF NEED
Pulmonary arterial hypertension (PAH) is a complex, progressive disease characterized by continuous high blood pressure in the pulmonary arteries. As the disease advances, elevated arterial pressure increases stress on the heart as it attempts to pump blood into the lung's thickening arteries. Over the course of the disease, the heart muscle weakens, losing its ability to pump enough blood into the lungs. Patients with PAH experience shortness of breath, fatigue, dizziness, and chest pain, among other symptoms, and are often not diagnosed until later in the disease process. PAH has an enormous impact on a patient's ability to function, perform simple everyday activities, and quality of life.
There is no cure for PAH, and it may be idiopathic or associated with other conditions such as scleroderma, lupus, rheumatoid arthritis, or HIV. It affects more than 100,000 people of all ages and ethnic backgrounds in the US. The year 2001-when the first oral medication was approved specifically for the treatment of PAHmarked the beginning of a new era in PAH management. Prior to then, effective treatment often required travel to specialized centers which many patients did not or were unable to do. In recent years, PAH treatment has advanced as more options have become available. It is clear, however, that the most effective management of PAH occurs when healthcare providers, patients, and their loved ones take active roles in learning about the disease and developing a comprehensive treatment plan.
This program is designed to present healthcare providers with the most up-to-date information about the PAH disease process, early signs and symptoms of the disease and those populations at increased risk of developing PAH, a greater understanding of available treatment options, and the importance of effective disease management.
TARGET AUDIENCES
The continuing medical education (CME) course is designed for cardiologists, pulmonologists, rheumatologists, primary care physicians, physician assistants, and nurses.
PROGRAM OBJECTIVES FOR HEALTHCARE PROVIDERS
At the conclusion of this symposium, participants will be better able to:
• Discuss the epidemiology, pathogenesis, and pathophysiology of PAH, including best approaches for classifying the disease in their patients
• Identify early signs and symptoms of PAH as well as those patient populations at increased risk of developing the disease
• Review the most up-to-date information regarding the available treatment options and the importance of effective disease management
• Apply the learnings from the didactic presentations in a case study setting
CREDIT DESIGNATION STATEMENT
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Michigan Medical School designates this activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE STATEMENT
The University of Michigan Medical School endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the Association of American Medical Colleges requiring that the sponsors of continuing medical education activities and the speakers at these activities disclose significant relationships with commercial companies whose products are discussed in the educational presentations. Disclosure of relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Detailed information will be provided in the meeting handouts. There is an increasing appreciation of inflammation in clinical pulmonary arterial hypertension (PAH). While the controversy remains as to how inflammation may contribute to the pathogenesis of this disease, new avenues of research into this frequently fatal condition are opening as the immune system is being more carefully considered. A variety of diverse inflammatory diseases ranging from viral infections to connective tissue disorders can culminate in pulmonary vascular pathology that is indistinguishable. This review discusses some of the immunobiology that may unite these seemingly unrelated conditions. Inflammation in PAH has been relatively well described, 1 but whether inflammation is cause or consequence in the pathogenesis of this disease remains undetermined. Severe PAH can be a manifestation of a number of collagen vascular diseases and viral infections. These associated conditions are also either characterized by or have a propensity for autoimmunity. This review will take into account known immune disturbances in PAH and how these events may be early contributors to vascular injury that may contribute to the development of this life-threatening condition.
PROGRAM
Pulmonary Arterial Hypertension: Inflammation, Immunodeficiency, and Autoimmunity
Plexiform lesions in PAH lungs are often accompanied by an inflammatory cellular exudate consisting of macrophages, mast cells, and lymphocytes (Figure 1) . [2] [3] [4] Additionally, the presence of antibody-complement deposits have been Advances in Pulmonary Hypertension 27 described in several conditions associated with PAH. 5, 6 The presence of known systemic autoimmunity in PAH-associated conditions suggests that this inflammation could also impact lung circulation. It has been recognized for more than 40 years that there are associations between autoimmune conditions, such as systemic lupus erythematosus, and severe PAH.
In addition to this well-recognized association with autoimmune disorders, there is a link between viral infections, immune insufficiency, and PAH ( Table 1) . For example, patients who are HIV positive and patients with AIDS are at a higher risk for developing PAH. As with HIV infection, most conditions associated with PAH are associated with a defect in the CD4 T cell compartment, meaning that these conditions are characterized by an absolute deficiency of CD4 cells, a decreased CD4/CD8 ratio, and/or a diminished relative percentage of CD4 + CD25
+ cells, the putative regulatory T cell (T reg ) subset. Furthermore, PAH has been described following splenectomy. 7 Additionally, it was recently reported that a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is caused by a mutation leading to the loss of function of the autoimmune regulator (AIRE) protein, died with fatal idiopathic PAH (IPAH). 8 The AIRE gene is of central importance in the development of thymus-dependent selftolerance.
Our group has also recently noted that athymic nude rats, which lack T cells, have significantly worse PAH in response to vascular epithelial growth factor receptor antagonism treatment than do euthymic nude rats that have a normal complement of T cells. 9 In this setting of T-cell immunodeficiency, animals develop severe PAH under Denver altitude conditions (ie, chronic severe hypoxia is not required to develop PAH).
It is estimated that 30% to 40% of the patients with IPAH are antinuclear antibody positive, 23% anti-Ku antibody positive, and another 10% to 15% of those patients may express antiphospholipid antibodies. [10] [11] [12] A unifying hypothesis that addresses these cumulative findings is that in the setting of relative or absolute immunodeficiency, immune dysregulation likely occurs and may lead to the activation of pathogenic autoreactive B cells and T cells.
Immune Dysregulation in PAH: Lymphocytes, Antibodies, and Mast Cells
Whether injury incurred by T cells or B cells in PAH is important in disease development is currently unknown. However, it is well established, as a general immunologic principle, that in the absence of regulation exerted by a population of regulatory T cells over B cells, autoantibodies will arise and autoimmune disease can develop. 13 With absent or diminished T reg activity, other cells (such as mast cells) presumably provide stimulatory signals to relevant self-reactive B cells, rescue them from apoptosis, and stimulate them to form pathogenic antibodies.
14 Antibodies directed against the vascular endothelium could certainly promote endothelial apoptosis, and antiendothelial antibodies (AECAs) are present in autoimmune disorders associated with PAH including systemic lupus erythematosus, 15 mixed connective tissue disease, 16 and scleroderma. 17 In lupus and Sjögren syndrome, antibody and complement deposits have been localized in the walls of pulmonary arteries of patients with PAH. 5, 6 Scleroderma and the antiphospholipid antibody syndrome (APS) are 2 syndromes that may demonstrate how dysregulated immunity can potentially contribute to the development of PAH. Not only are absolute lymphocyte counts reduced in scleroderma, 18, 19 but patients with scleroderma also have relatively fewer CD4 + CD25
+ cells in the peripheral circulation compared to healthy controls. 20 Similarly, patients with APS have altered peripheral T cell subsets; most notably in a significantly reduced CD4 + CD25 + population. 21 Both conditions are associated with AECAs capable of inducing endothelial cell apoptosis, [22] [23] [24] which may be the first event implicated in systemic disease development. 25 An instigating injury to endothelial cells in scleroderma and APS that can trigger autoantibody formation may be a viral infection that leads to immunomodulatory effects. [26] [27] [28] In this setting of T reg activity, a dysregulation of B cells is also observed. 29 Plexiform lesions found in the arterial walls of patients with sclerodermal PAH include an inflammatory infiltrate 30 consisting of macrophages, T cells, B cells, and mast cells 31, 32 ; whereas APS can be associated with pulmonary capillaritis. 33 In summary, scleroderma and APS are disorders characterized by perivascular inflammation associated with possible viral infection, endothelial damage, diminished peripheral CD4 + CD25
+ cells, dysregulated B cells, and AECAs. Figure 2 presents a putative model of this process.
Inflammatory Chemokines and Cytokines in PAH
Inflammatory mediators in patients with PAH are readily detected in the circulation. For example, patients with the syndrome plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) associated with PAH, exhibit increased levels of TNF-α, soluble TNF-receptor type I, IL-2, soluble IL-2 receptor, IL-6, and interferon-Á. 34 Similarly, IPAH patients exhibit markedly elevated IL-1 and IL-6 serum levels. 
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FKN/CX3CL1 is a chemokine which is upregulated in CD4+ and CD8 + cells in PAH. 36 Regulated on Activation, Normal T Expressed and Secreted (RANTES, also known as CCL5) is a key cytokine member of the interleukin-8 superfamily of cytokines that is upregulated in the inflammatory milieu of PAH lungs. 37 RANTES is a selective attractant for memory T cells and monocytes that also stimulates endothelin converting enzyme-1 and endothelin-1, a potent vasoconstrictor that may also contribute to increased vascular resistance in PAH. 38 Thus, these cytokines and chemokines in PAH patients may act to further target immune cells to lung circulation.
By focusing on the phenomena of inflammation in PAH, and by incorporating what is known from clinical disease and from experimental models, there should be increasing understanding of how the immune system contributes to this lethal disease. It is conceptually possible that appropriately targeted immunotherapies initiated in a timely fashion will have the potential to attenuate or even reverse this frequently relentless condition. Echocardiography is noninvasive and has high sensitivity and specificity for diagnosing pulmonary hypertension (PH). It allows the assessment of right and left valve integrity and hemodynamic parameters. In patients with suspected or known PH, echocardiography can delineate left ventricular (LV) systolic and diastolic dysfunction, and detect congenital heart defects or valvular heart disease. Whereas the echocardiographic assessment of LV function is well established, internationally standardized methods to quantitate right ventricular (RV) function are less well known and reproducible. This is due to the complex, crescentic nature of RV geometry. 1 This article summarizes a practical approach using echocardiography for evaluating patients with PH.
RV Pump Function
Manifest PH leads to an enlargement of the RV and atrial areas and to eventual RV dysfunction. The evaluation of the RV size and function in patients with PH may be more prognostically important than the simple estimation of the tricuspid regurgitation velocity. 2 As a general rule the right ventricle, as seen from the apical 4-chamber view, should normally not exceed LV dimensions (Figure 1) . If the right heart and/or right atrium are enlarged, further evaluation is usually warranted, particularly in patients with resumed PH. However, the crescent-shaped form of the right ventricle, particularly as it wraps around the left ventricle makes it difficult for direct calculation of RV dimensions and ejection fraction. 1 Whereas the action of the LV with its circular myocardial fibers is similar to a syringe, the functional geometry of the RV makes its action more like a bellow, with little excursions of the RV wall moving a large volume. In the longitudinal view, the right ventricle is similar to a triangle, while in the cross-section it is tall and thin. 3 It is not possible to completely visualize the right ventricle in one single, 2-dimensional echocardiographic view. Thus, accurate assessment of the right heart requires multiple echocardiographic views, including parasternal long-and short-axis, RV inflow, apical 4-chamber, and subcostal views.
1 Assessment of ventricular ejection fraction with the modified Simpson rule is not accurate in defining RV systolic function. Various approaches, including real time 3-dimensional transthoracic 4 or transesophageal 3-dimensional echocardiography rately but are less applicable in routine examinations. The first step in the routine evaluation of the right ventricle is the visual qualitative assessment of global systolic function in different views. With this type of examination, the RV systolic function is classified as normal, slightly, moderate, or severely impaired. When the left ventricle is deformed and/or there is a pericardial effusion, frequently more than RV function is severely impaired (Figure 1) . The degree of LV distortion caused by the enlarged right ventricle can be further quantified using the LV eccentricity index (Figure 2) . 6 In the short axis, the left ventricle is usually round with equal across and longitudinal diameters. In case of RV enlargement with deformity of the left ventricle, the across diameter is shorter than the longitudinal one, resulting in an eccentricity index above 1.2, which is abnormal.
Further, routine views may be useful in characterizing the patient with PH. In the short-axis view, the RV outflow tract and the central pulmonary artery can be evaluated. The main pulmonary arteries and their major branches are often dilated in patients with severe PH (Figure 3) . Early recognition of an aneurysm of the central pulmonary artery is important, since dissection or even rupture can occur suddenly with excessive changes in intrathoracic pressure. 7 The tricuspid annular plane systolic excursion estimates RV systolic function by measuring the level of systolic excursion of the lateral tricuspid valve annulus toward the apex. In systole, the tricuspid annulus will normally move toward the apex approximately 1.5 to 2.0 cm. Tricuspid annular excursion of less than 1.5 cm is noted with severe RV dysfunction and is associated with a poor prognosis. 8 Additional assessments of RV systolic function include tissue Doppler imaging (TDI) of tricuspid annular velocity or RV index of myocardial performance (Tei) . The velocity of the lateral tricuspid annulus can be obtained by TDI. Velocities less than 10 cm per second reflect an abnormal RV function. 9 For calculation of the Tei index, RV ejection time can be obtained within pulsed wave (PW)-Doppler in the RV outflow tract. The Tei index can be calculated with the formula: isovolumic contraction time + isovolumic relaxation time/ejection time. 10 When myocardial function deteriorates, ejection time is shortened and the pre-ejection and isovolumic relaxation periods are lengthened. This index is unaffected by heart rate, loading conditions, or the presence and severity of tricuspid regurgitation. 10 A Tei index greater than 0.40 can be associated with an abnormal global RV function with a sensitivity and specificity of 100% and 35%, respectively. In addition, strain is a new echocardiographic parameter that allows the assessment of regional RV function; however, its clinical value remains to be proven.
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Pulmonary Artery Pressures at Rest and During Exercise
Continuous wave (CW)-Doppler guided by color Doppler is the best method to obtain tricuspid regurgitant jet velocity (Figure 4) . 12 In the absence of pulmonic valve stenosis or outflow tract obstruction, systolic pulmonary artery pressure (PASP) can be estimated using the Bernoulli equation: [tricuspid regurgitant jet velocity (V) 2 x 4] + estimated right atrial pressure (RAP). 12 If the inferior vena cava is less than 20 mm in diameter and collapses with respiration, 5 mmHg should be added for RAP; 10 mmHg if it is greater than 20 mm but with inspiratory collapse, and 15 mmHg when the diameter is above 20 mm without variation with inspiration. 13 Tricuspid regurgitation jets are detectable in 39% to 86% of patients 14, 15 and the derived PASPs correlate well with invasively obtained values at rest 12 and during exercise. 16, 23 However, in a significant number of patients, PASP values are over-or underestimated. 17 Invasive 18, 19 and noninvasive 16, 20 studies note that PASP at sea level in healthy subjects younger than 50 years does not exceed 40 mmHg at rest. In athletes, PASP values can exceed 40 mmHg during higher workloads. 21 Pulmonary diastolic pressure can also be estimated by Doppler echocardiography and correlates well with invasive measurements. 22 An exaggerated PASP response to exercise can identify persons susceptible to high altitude PH 20 and allow screening of at-risk family members of patients with idiopathic pulmonary arterial hypertension (PAH). 23 Thus, stress echocardiography during supine bicycle exercise may be a useful screening method to identify persons at risk for developing PH. At minimum, echocardiography at rest should be performed in persons with a clinical suspicion of PAH.
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Summary
Further echocardiographic assessments in patients with PH should include the analysis of LV systolic and diastolic function, as well as valvular evaluation to exclude congenital heart disease. Left ventricle diastolic function should be examined by both PW-Doppler and tissue Doppler imaging. An impairment of the early phase of LV diastole is the most common type of dysfunction seen in patients with chronic PH, with reduced early to late diastolic filling ratio and diminished LV end-diastolic volume, which contributes to a reduced LV stroke volume. 25, 26 Echocardiographic predictors of poor prognosis in patients with PH include the occurrence of a pericardial effusion, 27, 28 an enlarged right atrium (Figure 5) , 27 a Tei index of at least 0.83, 29 an RV myocardial performance index greater than 1.4, 30 a dilated inferior vena cava, 31 and an eccentricity index greater than 1.2. 32 Interestingly, pulmonary artery systolic pressures are not independent predictors of prognosis.
Echocardiography is an important tool in terms of both diagnosis and prognosis in PH. Techniques to quantify the RV function should be further evaluated and may include the strain and TDI for determination of regional RV pump function, and stress echocardiography for identification of subjects at risk for PH and as a follow-up tool. 2 is pathologic and associated with a poor prognosis. 27 Normal values of indexed right atrial volumes are similar to left atrium (21 m1/m2).
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Dr Fagan: I would first like to acknowledge your efforts, Greg, in organizing the meeting with your committee. I know that we all agree that the meeting was a great success. The Scientific Sessions of PHA this year focused on three major themes: the importance of inflammation, the importance of genetics, and new evolving imaging modalities in the diagnosis and monitoring of patients with pulmonary arterial hypertension (PAH). Greg, perhaps you can provide your thoughts on why you and the committee chose these topics for the Scientific Sessions.
Dr Elliott: The three subjects are very important and potentially linked. For example, one thinks about the inherited basis of pulmonary arterial hypertension as providing susceptibility. We know that not everyone with mutations will ultimately develop disease and so we must consider that there are other stimuli that lead to disease in genetically susceptible individuals. Inflammatory conditions or mediators may be an additional stimulus in a susceptible host, especially given the relationship of PAH with inflammatory diseases. The lectures on imaging may provide us with tools for earlier detection, which is very important for a disease that often remains silent for so long, and is only discovered at the later stages. Obviously, being able to recognize the disease earlier will allow us either to prevent it from ever occurring or at least to modify the course before irreversible pathologic changes occur. The themes, I think, for me were always interconnected and had a lot of potential for the audience.
Dr Badesch: The first major talk, Paul Ridker's talk on inflammation and systemic vascular disease was outstanding. He emphasized how well developed the theme of inflammation is in systemic vascular disease and he focused quite a lot on CRP (C-reactive protein) as a marker of systemic vascular inflammation, looking at it in a variety of systemic vascular disease processes. I thought that was a wonderful introduction to inflammation in vascular disease, and it helps us to realize what we need to be looking at in pulmonary vascular disease. That was followed by a great talk by Norbert Voelkel on inflammation in pulmonary arterial hypertension.
Dr Fagan: One of the things that was important about Dr Ridker's talk was that he really demonstrated how high quality translational research using patients with systemic vascular diseases has opened up an entire new paradigm of thinking in that disease. He has shown us the potential we have to look at similar themes in our patients and to open up entire new avenues ultimately, hopefully, leading to therapies in our patients. And I thought that bringing someone in who has done such terrific work in the systemic circulation really was a tremendous addition to the discussion of the pulmonary circulation. Norbert's talk showed us some of the mounting evidence of inflammation in PAH and the possibility that autoimmunity plays a role. Clearly, more work will need to be done but perhaps, like in the systemic circulation, this may represent a new or additional paradigm for the pathogenesis of PAH. ible infrastructure to conduct population biology studies. He can store many thousands of samples. They are not only catalogued, but correlated with the relevant clinical information. He can pull from that bank of samples to look at biomarkers in systemic vascular disease and he has published many studies from those samples, and it is something from which we can learn. We have done a number of clinical trials, and we probably have not done such a great job of storing clinical samples on our patients for future analysis. His work shows the value of that kind of bank of biologic samples that are correlated with clinical information.
Dr Fagan: You have made an excellent point. Another area where access to stored samples and clinical data might be useful is in assessing the response to specific therapies. As an example, are there inflammatory markers (ie, CRP?) that change with treatment? Do these changes correlate with clinical outcome measurements? Like you, I came away with the idea that we should be storing these materials. This would allow investigators to test a hypothesis in a large sample of patients. It is going to be very helpful at some point to also link specific biomarkers to the disease and begin to use these to predict who is at risk. It would be great to have a "screening" test for PAH. So, I think the opportunities with stored samples and identifying biomarkers exist in at least two areas: one is identifying progression of disease and response to therapy, and another in predicting who is at risk.
Dr Frantz: I certainly agree with all of those comments. It was also wonderful to hear Dr Valentin Fuster talking about the imaging aspects in terms of MRI, looking at the right ventricle, and potentially getting to a point where we may be able to get an image of the pulmonary vasculature as well. I think all of us feel that we are on the cusp of a new era targeting inflammation and proliferation, going beyond simple vasodilators, and looking at this not only as an issue of prognostic inflammatory markers, but also better understanding the pathophysiology and the effect of treatment on the vasculature. So much work to date in the treatment of pulmonary hypertension has focused on improving the six-min-ute walk and short-term hemodynamic results. We are heading in the direction of understanding the pathophysiology, the genetics, the proteomics, and targeting vascular inflammation and then having to define endpoints to be able to decide if we are impacting on that. And so, it really is exciting to see the developments in these areas.
Dr Fagan
probably can and should measure to evaluate patients with PAH or as screening tests for persons at risk for disease. Along those lines was Ekkehard Grünig's presentation about the usefulness of exercise or stress echocardiography in looking at first-degree relatives of patients with PAH and whether or not that may impact how we think about the families of some of our patients.
Dr Frantz: I agree. The exercise echo in that population is interesting, but our own experience with exercise echo is that it is sometimes hard to interpret. There is such a range of pressure response in patients who may be at lower risk that I don't always know what to do with the information. Certainly, as we identify more patients who carry genetic receptor abnormalities with the risk of PAH, may-be early intervention will be something that we can do. It is really astonishing though when we think about the penetrance of this disease as only being in the range of 20% in families who carry the BMPR2 mutation. It is surprising, really. It just raises the question, why more of them don't develop it. The key may be looking for modifier genes that may seem important.
Dr Elliott: I agree. Maybe I could follow up on your point and ask you, as a cardiologist, if you had an exercise echocardiogram that suggested the presence of pulmonary arterial hypertension, would your confidence level still be low enough that you would want to perform right heart catheterization to confirm or refute the presence of pulmonary hypertension? Dr Frantz: Absolutely. I view a positive stress echo in terms of rising PA pressures by echo estimates as a risk factor for exercise-related pulmonary hypertension and have felt fairly strongly about taking the patient to the catheterization laboratory. There we do supine bike exercise with the Swan-Ganz catheter in place, to confirm whether those pulmonary artery pressures are, in fact, rising to the extent that they may appear to on exercise echo. We know that the respiratory excursion with exercise is substantial and the intrathoracic pressure swings are huge, and trying to image the tricuspid regurgitant signal during exercise echo is difficult. I have certainly had the experience of having patients referred for the testing of exercise-related pulmonary hypertension based on stress echo, only to put a catheter in and Certainly, as we identify more patients who carry genetic receptor abnormalities with the risk of PAH, maybe early intervention will be something that we can do. It is really astonishing though when we think about the penetrance of this disease as only being in the range of 20% in families who carry the BMPR2 mutation. It is surprising, really. It just begs the question, why more of them don't develop it. The key may be looking for modifier genes that may seem important.
-Dr Frantz
Images from PHA Scientific Sessions: Pulmonary contrast-enhanced magnetic resonance angiography depicts normal pulmonary artery.
really find that the pressures weren't rising nearly as much as was suspected on the stress echo.
Defining stress-induced or exercise-induced PH Dr Badesch: I was just going to ask all three of you how you would define stress-induced pulmonary hypertension or exercise-induced pulmonary hypertension. It would be interesting to know if our definitions are similar or not, and is it the same for all patients? Is the definition the same say, for an obese, deconditioned patient who demonstrates a rise in pulmonary arterial pressure with exercise, as it is for someone else? What do you call pulmonary hypertension with exercise? Is there a threshold?
Dr Elliott: David, let me clarify. Are you asking all three based on echocardiography?
Dr Badesch: Either echo or hemodynamics.
Dr Frantz: I feel we have to also look at the systemic pressure and the cardiac output response, in the sense that if you have a performance athlete who can generate incredibly high cardiac output, and may push the systemic pressure to 200 systolic, the PA pressure may go up to 60 to 70 mmHg systolic in some of these patients who would otherwise be considered normal, and so the pulmonary vascular resistance at those higher flows may be normal. Many of the patients we see can't exercise that vigorously, but their systemic blood pressure response is extremely variable. They may generate in the cath lab a pulmonary artery systolic pressure of 60 mm of mercury with a systemic pressure of 180, and a cardiac output of 12 liters per minute, and I don't think that is an abnormal response. I personally think it is a relatively murky area in the sense that to look at what happens in the normal population you have to go back to some very old literature, where the PA pressure variability during exercise is quite remarkable.
Dr Badesch: I think that the definition probably varies depending upon the patient population you're looking at. My guess is that none of us have a good definition for exerciseinduced pulmonary hypertension. Greg, my best guess from the literature is that if the estimated PA systolic pressure is greater than 45 mmHg with exercise, it is considered by some to represent pulmonary hypertension, but I don't personally consider that to necessarily be true.
Dr Elliott: David, we looked at this a number of years ago, particularly when we had so many of these echocardiograms performed in people who had taken anorexigens and it seemed to us that the definition of an estimated PA systolic pressure above 45 mm of mercury identified a population in whom you might find pulmonary hypertension. However, unless the PA systolic estimate was above 60 mm of mercury, I am not confident that I'll find pulmonary hypertension at right heart catheterization. So, I think it is hard to draw a threshold and certainly there are false positives and false negatives, depending upon the population whom you are testing and the pretest probability. Obviously, we can encounter lots of false positives when we are dealing with a population that should be healthy as opposed to a population that has other evidence that they may have pulmonary arterial hypertension. So, as I think you've said, and emphasized, this is a difficult area, the echo estimates of pulmonary pressure, whether at rest or with exercise.
Dr Fagan: Given that concern, the notion of focusing on patients who may be at risk, to limit the false positive rate, might be the more reasoned approach. I think Ekkehard Grünig is doing this in Germany. He is focusing on family members, on those who may have an additional risk factor.
Screening patients with scleroderma
Dr Badesch: Another population that I have heard suggested for screening with exercise echocardiography, and I think there is an investigator looking at this, is the scleroderma population. The thought is that it might be possible to identify patients with a propensity toward the development of pulmonary hypertension earlier. You are right, Karen, selecting that proper patient population and then doing a formal screening study probably makes sense.
Dr Elliott: David, knowing that you are a very good pulmonologist, I might ask you, would you use an exercise echo to screen those patients, assuming that there weren't any musculoskeletal limitations to exercise, or what do you think about the DLCO as a screening test?
Dr Badesch: An isolated fall in diffusing capacity may be another means of early identification of pulmonary vascular disease in patients with scleroderma. So, both exercise echocardiography and the DLCO may be good tools.
Dr Frantz: And then of course, we would need to see if identifying them early and intervening really has an impact. All of us are trying to get at this issue. We know, especially in patients with scleroderma, that once they develop severe gas exchange problems with very low diffusing capacity for carbon monoxide and severe pulmonary hypertension, they often don't respond well to our therapies. We are getting better at identifying the patients early, because the rheumatologists refer them, and then we may be left with a situation of mild pulmonary hypertension at rest, or exercise-related pulmonary hypertension, or maybe their DLCO is 50% of predicted. We know that they are developing some gas exchange trouble and then I suppose we really need to do PHA has done a terrific job of lobbying Congress and certainly the Pulmonary Hypertension Clinicians and Researchers Organization has been good at keeping us aware of funding opportunities as well. If we can understand the biology of pulmonary hypertension, it has so much applicability to the pathobiology of other disorders. Pulmonary hypertension may be a relatively rare disease but the role of inflammation and proliferation applies to many other diseases. -Dr Elliott "Individuals whose lives are impacted by pulmonary hypertension have the right to fight back as much as they are able and willing."
These words have defined and driven the rapid growth and success of the Pulmonary Hypertension Association. PHAware -Our success ultimately lies in our ability to tell our own compelling stories. PHAware is a grassroots campaign that gives patients, medical professionals, and other advocates everything needed to develop media contacts in our own communities.
Faces of PH -Just as PHAware is designed to get our stories out at the local level, this national media campaign showcases 10 patient-physician pairs in mainstream media in 10 major cities. some randomized studies to see if intervening early could have an impact. I would view them as being more of a concern if they have a combination of a low DLCO, plus a tendency to exertional hypoxemia, and a pulmonary arterial pressure with exercise that seems disproportionate for their situation.
Dr Elliott: In our experience the falling DLCO often is caused by another process such as alveolitis and not always pulmonary arterial hypertension.
Dr Frantz: Karen, do you have a particular pressure elevation in the cath lab that you take as being diagnostic of exercise-induced pulmonary hypertension?
Dr Fagan: No, not really. And, again, I don't think that we have enough experience to really know. We could use the classic hemodynamic definition of a mean pulmonary pressure greater than 30 with exercise. Should we be looking at the pressure elevation or should we be looking at the resistance calculations? Perhaps in exercise it is not so much the pressure elevation, but whether or not there is a significant change in the resistance, and the best way to measure resistance, is to go into the cath lab and have a patient exercise. I think that that recruitment and distensibility of vessels with exercise, or lack of these responses in pulmonary vascular disease may be very important. Measuring resistance is one way to evaluate this.
Lean times ahead for research funding
Dr Fagan: I want to change topics slightly but it is certainly related to the overall mission of the Scientific Sessions. There is concern regarding a decrease in funding of clinical as well as basic science research over the next few years. How do you think this will impact research in pulmonary circulation? I think including this in the discussion of the Scientific Sessions provides a good opportunity to see what kind of impact we think this will have in the near future.
Dr Badesch: Unfortunately, I think it is going to negatively impact investigator-initiated studies. This would include basic research studies as well as translational studies. In the clinical arena we have previously been fairly heavily dependent upon support from the pharmaceutical industry in investigating new forms of therapy. As we may want to soon look at more novel therapies, perhaps initially in smaller pilot studies, I think that obtaining adequate funding may be challenging. The next family of studies, if you will, ought to be of agents that have antiproliferative and antiinflammatory activity. My guess is that it might be somewhat challenging to convince the pharmaceutical industry that those kinds of studies are worthy of a large investment, without pilot data. Funding for smaller scale pilot clinical studies will need to come from sources like the NIH. I do believe that such funding is going to be very challenging to obtain. There are a number of novel agents out there that we might want to look at, and it would certainly be advantageous to have support from the NIH and other funding agencies.
Dr Frantz: I am sure that it will be difficult, although it will improve if the NIH continues to support the PAH SCOR proposals, where at least half the projects had to be clinically based. Focused physiologic studies that look at novel approaches toward inflammation, or combination therapies, and studies incorporating cardiac and pulmonary imaging are important avenues for exploration. I think the NIH has some level of commitment to clinical trials in pulmonary hypertension and not just the basic science work. Some of these projects may take novel collaborative effort between industry and government and there has been precedent for that in other areas such as heart failure, where device companies are partners with the NIH in clinical trials.
Dr Fagan: Yes. It is going to be an interesting few years, and the pendulum will likely swing back toward improved funding again. It is a matter of sustaining our momentum forward during the leaner times, so that we don't stall in acquiring new knowledge. And I think partnerships with the NIH and industry are certainly one way to help maintain that momentum forward but we need continued commitment from the NIH. Do you think there is any additional role to what PHA is already doing in terms of advocating for research funding with our legislators? Are there other things PHA as an organization might be able to do?
Dr Badesch: PHA has demonstrated support for clinical investigation. We're trying to put together a multicenter clinical trial looking at anticoagulant and antiplatelet therapy in PH, and PHA has not only been supportive of that effort, but has actually tried to facilitate cooperative funding between the NIH and a foundation. This is a very positive contribution from PHA. Dr Elliott: Absolutely. PHA has done a terrific job of lobbying Congress and certainly the Pulmonary Hypertension Clinicians and Researchers Organization has been good at keeping us aware of funding opportunities as well. If we can understand the biology of pulmonary hypertension, it has so much applicability to the pathobiology of other disorders. Pulmonary hypertension may be a relatively rare disease but the role of inflammation and proliferation applies to many other diseases. I think the opportunities, although they may be more competitive than years past, will be focused on funding of novel projects that will affect pulmonary hypertension.
The next PHA Scientific Sessions: an exciting agenda, a broad spectrum of topics Dr Fagan: Greg, that gets back to one of the original concepts that you and your committee had for the Scientific Sessions, which was to network with investigators from other areas to stimulate new ideas and potential collaborations. I felt that you certainly achieved this goal. Are there any ideas anyone has for the next Scientific Sessions? Any general themes that 2 years from now would be good to focus on? Dr Badesch: I wonder if in a couple of years we might be ready to hear about pharmacogenomics. Would our therapies be more effective if we were able to select the appropriate patient population? That's an area of tremendous growth in medicine right now. My guess is that studies being conducted by Ray Benza and others might give us enough information to begin talking about pharmacogenomics and pulmonary hypertension.
Dr Elliott: David, pharmacogenomics would be an excellent topic to put on the agenda for the next conference. We have our toe in the door of the pulmonary circulation, but there are so many other areas that have focused on this important topic. For example, in cancer there are many genomic markers being used to predict and identify response to cancer chemotherapies.
Dr Frantz: It may also be relevant to focus on which factors we should be following for prognosis. It's an amazingly complex decision about when to change therapy, when to move to lung transplant, and how to integrate RV function, BNP levels, and functional class. A prognostic model remains an important topic.
Dr Elliott:
Remember there were two SCORs in pulmonary vascular disease awarded this cycle so hearing from someone in those programs, in basic and clinical areas, would be another good topic for the conference. 
• Follow the Results From the Next Generation of Clinical Trials
Please see brief summary of prescribing information on adjacent page. REVATIO is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability. The efficacy of REVATIO has not been evaluated in patients currently on bosentan therapy. The use of REVATIO and organic nitrates in any form, at any time, is contraindicated. Co-administration of REVATIO with potent CYP3A4 inhibitors, eg, ketoconazole, itraconazole, and ritonavir, is not recommended as serum concentrations of sildenafil substantially increase. Before starting REVATIO, physicians should consider whether patients with underlying conditions could be adversely affected by the mild and transient vasodilatory effects of REVATIO on blood pressure. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of REVATIO to these patients is not recommended. Should signs of pulmonary edema occur when sildenafil is administered, the possibility of associated PVOD should be considered. Patients with the following characteristics did not participate in the preapproval clinical trial: patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months, unstable angina, hypertension (BP>170/110), retinitis pigmentosa, or patients on bosentan. The safety of REVATIO is unknown in patients with bleeding disorders and patients with active peptic ulceration. In these patients, physicians should prescribe REVATIO with caution. Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely post-marketing in temporal association with the use of PDE5 inhibitors for the treatment of erectile dysfunction, including sildenafil. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to seek immediate medical attention in the event of sudden loss of vision while taking PDE5 inhibitors, including REVATIO. The most common side effects of REVATIO (placebo-subtracted) were epistaxis (8%), headache (7%), dyspepsia (6%), flushing (6%), and insomnia (6%). Adverse events were generally transient and mild to moderate. *Actual pharmacy or out-of-pocket costs may vary. Price comparisons do not imply comparable efficacy or safety. The clinical trial for REVATIO included patients who were predominantly functional classes II and III, and the clinical trial for the other oral PAH treatment included patients who were predominantly functional class III.
S T A R T W I T H C O N F I D E N C E ™
REVATIO: for patients with PAH as early as class II
Proven effective for patients with Pulmonary Arterial Hypertension (WHO Group I)
• Increased 6-minute walk distance as early as week 4
• Significantly reduced mean pulmonary arterial pressure
In a long-term, uncontrolled extension study 94% of patients were still alive at 1year
• Walk distance and functional class appeared stable
• Without a control group, these data must be interpreted cautiously
The lowest-priced oral PAH therapy 1 *
• REVATIO 20-mg tablets tid REVATIO contains sildenafil citrate, the same active ingredient found in Viagra In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. There were infrequent reports of patients who experienced symptomatic postural hypotension. These reports included dizziness and light-headedness, but not syncope (see PRECAUTIONS: General).
Concomitant administration of oral contraceptives (ethinyl estradiol 30 μg and levonorgestrel 150 μg) did not affect the pharmacokinetics of sildenafil.
Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.
Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.
Effects of REVATIO on Other Drugs
In vitro studies: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 μM). In vivo studies: When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.
No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.
Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).
Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.
In healthy subjects, co-administration of 125 mg b.i.d. bosentan and 80 mg t.i.d. sildenafil resulted in a 63% decrease in AUC of sildenafil and a 50% increase in AUC of bosentan.
In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A4 substrates.
Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 μg and levonorgestrel 150 μg).
Carcinogenesis, Mutagenesis, Impairment of Fertility
Sildenafil was not carcinogenic when administered to rats for up to 24 months at 60 mg/kg/day, a dose resulting in total systemic exposure (AUC) to unbound sildenafil and its major metabolite 33 and 37 times, for male and female rats, respectively, the human exposure at the Recommended Human Dose (RHD) of 20 mg t.i.d. Sildenafil was not carcinogenic when administered to male and female mice for up to 21 and 18 months, respectively, at doses up to a maximally tolerated level of 10 mg/kg/day, a dose equivalent to the RHD on a mg/m 2 basis.
Sildenafil was negative in in vitro bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and in vitro human lymphocyte and in vitro mouse micronucleus assays to detect clastogenicity. There was no impairment of fertility in male or female rats given up to 60 mg sildenafil/kg/day, a dose producing a total systemic exposure (AUC) to unbound sildenafil and its major metabolite 19 and 38 times, for males and females, respectively, the human exposure at the RHD of 20 mg t.i.d.
Pregnancy
Pregnancy Category B. No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in pregnant rats or rabbits, dosed with 200 mg sildenafil/kg/day during organogenesis, a level that is, on a mg/m 2 basis, 32-and 68-times, respectively, the RHD of 20 mg t.i.d. In a rat pre-and postnatal development study, the no-observed-adverse-effect dose was 30 mg/kg/day (equivalent to 5-times the RHD on a mg/m 2 basis). There are no adequate and well-controlled studies of sildenafil in pregnant women.
Nursing Mothers
It is not known if sildenafil citrate and/or metabolites are excreted in human breast milk. Since many drugs are excreted in human milk, caution should be used when REVATIO is administered to nursing women.
Pediatric Use
Safety and Effectiveness of sildenafil in pediatric pulmonary hypertension patients has not been established.
Geriatric Use
Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, but studies did not include sufficient numbers of subjects to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger pulmonary arterial hypertension patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
ADVERSE REACTIONS
Safety data were obtained from the pivotal study and an open-label extension study in 277 treated patients with pulmonary arterial hypertension. Doses up to 80 mg t.i.d. were studied.
The overall frequency of discontinuation in REVATIO-treated patients at the recommended dose of 20 mg t.i.d. was low (3%) and the same as placebo (3%). In the pivotal placebo-controlled trial in pulmonary arterial hypertension, the adverse drug reactions that were reported by at least 3% of REVATIO patients treated at the recommended dosage (20 mg t.i.d.) and were more frequent in REVATIO patients than placebo patients, are shown in Table 1 . Adverse events were generally transient and mild to moderate in nature.
TABLE 1. Sildenafil Adverse Events in Ն3% of Patients and More Frequent Than Placebo
At doses higher than the recommended 20 mg t.i.d. there was a greater incidence of some adverse events including flushing, diarrhea, myalgia and visual disturbances. Visual disturbances were identified as mild and transient, and were predominately color-tinge to vision, but also increased sensitivity to light or blurred vision.
In the pivotal study, the incidence of retinal hemorrhage at the recommended sildenafil 20 mg t.i.d. dose was 1.4% versus 0% placebo and for all sildenafil doses studied was 1.9% versus 0% placebo. The incidence of eye hemorrhage at both the recommended dose and at all doses studied was 1.4% for sildenafil versus 1.4% for placebo. The patients experiencing these events had risk factors for hemorrhage including concurrent anticoagulant therapy.
In post-marketing experience with sildenafil citrate at doses indicated for male erectile dysfunction, serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, pulmonary hemorrhage, and subarachnoid and intracerebral hemorrhages have been reported in temporal association with the use of the drug. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity. Others were reported to have occurred hours to days after use concurent with sexual activity. It is not possible to determine whether these events are related directly to sildenafil citrate, to sexual activity, to the patient's underlying cardiovascular disease, or to a combination of these or other factors.
Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely post-marketing in temporal association with the use of PDE5 inhibitors when used in the treatment of male-erectile dysfunction, including sildenafil. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to seek immediate medical attention in the event of sudden loss of vision while taking PDE5 inhibitors, including REVATIO.
OVERDOSAGE
In studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses but rates were increased.
In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and it is not eliminated in the urine.
INDICATIONS AND USAGE
REVATIO is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability.
The efficacy of REVATIO has not been evaluated in patients currently on bosentan therapy.
CONTRAINDICATIONS
Consistent with its known effects on the nitric oxide/cGMP pathway (see CLINICAL PHARMACOLOGY), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using organic nitrates, either regularly and/or intermittently, in any form is therefore contraindicated.
REVATIO is contraindicated in patients with a known hypersensitivity to any component of the tablet.
WARNINGS
The concomitant administration of the protease inhibitor ritonavir (a highly potent CYP3A4 inhibitor) substantially increases serum concentrations of sildenafil, therefore co-administration with REVATIO is not recommended (see Drug Interactions and DOSAGE AND ADMINISTRATION).
REVATIO has vasodilator properties, resulting in mild and transient decreases in blood pressure (see PRECAUTIONS). Prior to prescribing REVATIO, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, for example patients with resting hypotension (BP <90/50), or with fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction.
Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended. Should signs of pulmonary edema occur when sildenafil is administered, the possibility of associated PVOD should be considered.
There is no controlled clinical data on the safety or efficacy of REVATIO in the following groups; if prescribed, this should be done with caution:
• Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months;
• Patients with coronary artery disease causing unstable angina;
• Patients with hypertension (BP >170/110);
• Patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases);
• Patients currently on bosentan therapy.
PRECAUTIONS
General
Before prescribing REVATIO, it is important to note the following:
• Caution is advised when phosphodiesterase type 5 (PDE5) inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including sildenafil, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly, leading to symptomatic hypotension. In the sildenafil interaction studies with alpha-blockers (see Drug Interactions), cases of symptomatic hypotension consisting of dizziness and lightheadedness were reported. No cases of syncope or fainting were reported during these interaction studies. Consideration should be given to the fact that safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and concomitant use of anti-hypertensive drugs.
• REVATIO should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease) or in patients who have conditions, which may predispose them to priapism (such as sickle cell anemia, multiple myeloma or leukemia). In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism (painful erections greater than 6 hours in duration) is not treated immediately, penile tissue damage and permanent loss of potency could result.
• In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. In vitro studies with human platelets indicate that sildenafil potentiates the anti-aggregatory effect of sodium nitroprusside (a nitric oxide donor). The combination of heparin and sildenafil had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans.
• The incidence of epistaxis was higher in patients with PAH secondary to CTD (sildenafil 13%, placebo 0%) than in PPH patients (sildenafil 3%, placebo 2%). The incidence of epistaxis was also higher in sildenafil-treated patients with concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist).
• The safety of REVATIO is unknown in patients with bleeding disorders and patients with active peptic ulceration.
Information for Patients
Physicians should discuss with patients the contraindication of REVATIO with regular and/or intermittent use of organic nitrates.
Sildenafil is also marketed as VIAGRA ® for male erectile dysfunction.
Drug Interactions
In PAH patients, the concomitant use of vitamin K antagonists and sildenafil resulted in a greater incidence of reports of bleeding (primarily epistaxis) versus placebo.
Effects of Other Drugs on REVATIO
In vitro studies: Sildenafil metabolism is principally mediated by the CYP3A4 (major route) and CYP2C9 (minor route) cytochrome P450 isoforms. Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. In vivo studies: Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance and/or an increase of oral bioavailability when co-administered with CYP3A4 substrates and the combination of CYP3A4 substrates and beta-blockers. These were the only factors with a statistically significant impact on sildenafil pharmacokinetics.
I N PA H , TA K E A I M AT E T-1 T H R O U G H E T A S E L E C T I V I T Y
In pulmonary arterial hypertension (PAH), endothelin (ET-1) exerts its cardiovascular effects through 2 receptors: ET A and ET B . When ET-1 activates the ET A receptor on the vascular smooth muscle, it leads to vasoconstriction and vascular remodeling. 4, 5 Endothelial ET B receptors mediate the release of vasodilating nitric oxide (NO) and prostacyclin (PGI 2 ), while inhibiting and clearing ET-1 from circulation. 5, 6 Blockade of ET B receptors may significantly impair the balance of endothelium-derived vasodilating substances. 4, 7 Endothelial dysfunction has been shown to improve with selective ET A blockade. 8 Hence, preemptive targeting of ET-1 through selective ET A receptor antagonism can slow the progression of PAH, and may even provide better overall outcomes. [2] [3] [4] 8 Imbalances in the key endothelial cell-derived mediators NO, PGI 2 , and specifically ET-1 are thought to be central to the pathogenesis of PAH. 9 NO and PGI 2 are potent vasodilators with antiproliferative activity. 10 ET-1 is a potent vasoconstrictor with proliferative activity. 5 Chronically elevated levels of ET-1 are associated with pulmonary vascular resistance, excessive scar formation and cardiac remodeling, cellular proliferation, and cardiac hypertrophy. levels are at least partly associated with impaired ET B receptor-mediated clearance. 13 Furthermore, the longterm administration of a selective ET B receptor antagonist was found to have unfavorable effects on vascular remodeling. 4 This is in sharp contrast to the benefits of selective ET A antagonism. 14 Vasoconstriction, cellular proliferation, and vascular remodeling are the hallmarks of PAH. 12 Studies have demonstrated that selective ET A antagonists play a pivotal role in the regulation of ET-1 levels in PAH and have been beneficial for vascular remodeling. 4, 7, 13 Highly selective ET A blockade maintains ET-1 clearance, NO and PGI 2 levels, and reduces or maintains circulating ET-1 levels, resulting in vasodilation, increased blood flow, and repair of remodeled vasculature compared to less selective agents. [5] [6] [7] 14 (See Figures 1,2) The more selective, the better. One should always be aware of the varying degrees of selectivity, as they equate to differences in blockade of the ET A and ET B receptors and resulting levels of ET-1. 8, 15, 16 Figure 3 illustrates the difference between a less selective agent and highly selective agents. These in vitro selectivity ratios demonstrate the stark differences in ET A selectivity. Figure 4 depicts how agents with low selectivity of the ET A receptor (<2400) increase ET-1 levels whereas highly selective ET A receptor (>2400) antagonists have been shown to decrease ET-1 levels or leave them unchanged. 6, 8, 15 The benefits of ET A selectivity are being recognized.
Currently, there are no highly selective ET A antagonists available for the treatment of PAH. In vivo studies have shown that highly selective ET A antagonism may lead to better overall outcomes. 
HOW SELECTIVE TO E T A SHOULD TREATMENT BE? THE DIFFERENCE LIES IN E T A SELECTIVITY
ET-1 AND RECEPTOR-MEDIATED ACTIVITIES TOWARD BETTER OUTCOMES IN PAH
